Results 241 to 250 of about 126,909 (281)

Discovery of Selective Inhibitors for In Vitro and In Vivo Interrogation of Skeletal Myosin II.

ACS Chemical Biology, 2021
Myosin IIs, actin-based motors that utilize the chemical energy of adenosine 5'-triphosphate (ATP) to generate force, have potential as therapeutic targets.
L. Radnai, M. Surman, Madalyn Hafenbreidel, Erica J. Young, Rebecca F. Stremel, Li Lin, Bilel Bdiri, Paolo Pasetto, X. Jin, Mackenzie Geedy, Joni-Rae Partridge, Aagam Patel, M. Conlon, J. Sellers, M. Cameron, Gavin Rumbaugh, P. Griffin, T. Kamenecka, Courtney A. Miller   +18 more
semanticscholar   +1 more source

Recent trend in the therapy of hypertrophic cardiomyopathy: Cardiac myosin inhibitors

2023
Cardiac myosin inhibitors are a new class of drugs that have recently been approved in obstructive hypertrophic cardiomyopathy. The main mechanism of action is to reduce the pathologically increased cardiac hypercontractility. Current drug therapies have not been demonstrated to modify the natural progress of the disease.
DEMİRKIRAN, Cahit, DEMİRYÜREK, Şeniz, DEMİRYÜREK, Abdullah Tuncay   +2 more
openaire   +1 more source

FDA approves first cardiac myosin inhibitor

Nature Reviews Drug Discovery, 2022
openaire   +1 more source

The Efficacy of Cardiac Myosin Inhibitors versus Placebo in Patients with Symptomatic Hypertrophic Cardiomyopathy - A Meta-Analysis and Systematic Review.

American Journal of Cardiology, 2023
Mohammad Yassen, Khalid Changal, Joshua Busken, Rachel Royfman, Eve Schodowski, B. Venkataramany, S. Khouri, G. Moukarbel   +7 more
semanticscholar   +1 more source

Omecamtiv Mecarbil in Systolic Heart Failure: Clinical Efficacy and Future Directions of a Novel Myosin-Activating Inotropic Agent

Cureus
Heart failure with reduced ejection fraction (HFrEF) remains a global health challenge, associated with high morbidity, mortality, and rising healthcare costs.
Mahmoud M Ramadan, Abdullah L Alshawi, Yasmeen A Mostafa, Mohammad T Al-Obeid, Mohammed Elmahal   +4 more
semanticscholar   +1 more source

FDA okays first cardiac myosin inhibitor

Nature Biotechnology, 2022
openaire   +1 more source

Update on Cardiac Myosin Inhibitors and Potential Role in Treating Obstructive Hypertrophic Cardiomyopathy

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2023
Michael J, Litt, Sharlene M, Day
openaire   +2 more sources

The Efficacy and Safety of Cardiac Myosin Inhibitors Versus Placebo in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.

American Journal of Cardiology
Chidubem Ezenna, M. Krishna, Meghna Joseph, Vinicius Pereira, Samia Nadeem, Gregory Valania, A. Goldsweig   +6 more
semanticscholar   +1 more source

Cardiac myosin inhibitors in the treatment of hypertrophic cardiomyopathy (literature review)

Pharmateca, 2023
L.V. Kononenko Kononenko, G.G. Taradin Taradin, G.A. Ignatenko Ignatenko   +2 more
openaire   +1 more source

Assessing The Efficacy And Safety Of Cardiac Myosin Inhibitors For The Treatment Of Hypertrophic Cardiomyopathy: A Meta-analysis Of Randomized Controlled Trials

Journal of Cardiac Failure
Chaitanya Rojulpote, M. Baig, Jason Siebert, A. Maligireddy, S. Shrivastava, William Frick, Somshukla Ghosh, Rabya Saraf, Priya Jain, Chien-Jung Lin, D. Verma, Deana Mikhalkova   +11 more
semanticscholar   +1 more source